---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-089813"
form_type: "8-K"
ticker: "HYPD"
cik: "0001682639"
company_name: "HYPERION DEFI, INC."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:11:16.267363+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Eyenovia Q2 net loss narrows to $6.2M; first Mydcombi sale post-FDA approval

## Summary
- Net loss for Q2 2023 was $(6.2)M ($0.16 per share), improved from $(7.2)M ($0.22) in Q2 2022; cash $17.5M as of June 30.
- First commercial sale of Mydcombi to Dr. Nathan Radcliffe; national launch expected in early 2024 after FDA approval.
- Apersure (Microline) presbyopia program advances; FDA provided clear path; registration batch manufacture planned for Q4 2023.
- R&D expenses $2.8M (down from $3.6M), G&A $3.1M (down from $3.5M); total op expenses $6.0M vs $7.1M YoY.
- Added to Russell 2000 and 3000 indexes; licensing partners Bausch+Lomb and Arctic Vision enrolling Phase 3 trials.

## SEC filing metadata
- accession: 0001104659-23-089813
- form_type: 8-K
- ticker: HYPD
- cik: 0001682639
- company_name: HYPERION DEFI, INC.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682639/000110465923089813/0001104659-23-089813-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682639/000110465923089813/tm2323259d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-089813
- JSON: https://secwatch.observer/filing/0001104659-23-089813.json
- Plain text: https://secwatch.observer/filing/0001104659-23-089813.txt

## Key facts
- Earnings Releases
  HYPERION DEFI, INC. reported the second quarter ended June 30, 2023 results: net income approximately $(6.2) million, or $(0.16) per share, EPS $(0.16) per share.
  - Period: the second quarter ended June 30, 2023
  - Net income: approximately $(6.2) million, or $(0.16) per share
  - EPS: $(0.16) per share
  - Result: reported results
  source text: On August 10, 2023, Eyenovia, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682639/000110465923089813/0001104659-23-089813-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.